These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 11439902)

  • 1. [Effect of macrolides on rat models of airway hypersecretion].
    Majima Y; Ishikawa M; Sugawara Y; Nakase K
    Jpn J Antibiot; 2001 Feb; 54 Suppl A():36-8. PubMed ID: 11439902
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect and action mechanism of short-term administration of clarithromycin for airway hypersecretion].
    Tagaya E; Tamaoki A; Kondo M; Nakada J; Nagai A
    Jpn J Antibiot; 2001 Feb; 54 Suppl A():33-5. PubMed ID: 11439901
    [No Abstract]   [Full Text] [Related]  

  • 3. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells.
    Shimizu T; Shimizu S; Hattori R; Gabazza EC; Majima Y
    Am J Respir Crit Care Med; 2003 Sep; 168(5):581-7. PubMed ID: 12829454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy.
    Rogers DF
    Monaldi Arch Chest Dis; 2000 Aug; 55(4):324-32. PubMed ID: 11057087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clarithromycin suppression of DNA synthesis by rat nasal mucosal cells enhanced by endotoxin instillation].
    Tonai A; Hashiba M; Baba S
    Jpn J Antibiot; 1997 Mar; 50 Suppl A():65-7. PubMed ID: 9678983
    [No Abstract]   [Full Text] [Related]  

  • 6. Macrolides attenuate mucus hypersecretion in rat airways through inactivation of NF-kappaB.
    Ou XM; Feng YL; Wen FQ; Wang K; Yang J; Deng ZP; Liu DS; Li YP
    Respirology; 2008 Jan; 13(1):63-72. PubMed ID: 18197913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory effects of a novel non-antibiotic macrolide, EM900, on mucus secretion of airway epithelium.
    Tojima I; Shimizu S; Ogawa T; Kouzaki H; Omura S; Sunazuka T; Shimizu T
    Auris Nasus Larynx; 2015 Aug; 42(4):332-6. PubMed ID: 25769240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New semisynthetic macrolides. Clarithromycin--its importance in the current therapy of bacterial infections].
    Iakovlev VP
    Antibiot Khimioter; 1999; 44(10):22-7. PubMed ID: 10635418
    [No Abstract]   [Full Text] [Related]  

  • 9. [Analysis of the mechanism of suppression on MUC5AC by macrolides--an analysis by using a chronic airway infection model].
    Yanagihara K; Kaneko Y; Ono H; Higashiyama Y; Miyazaki Y; Heisha Y; Gyo H; Asano K; Monda J; Tashiro T; Kawano S
    Jpn J Antibiot; 2004 Jun; 57 Suppl A():9-11. PubMed ID: 16108588
    [No Abstract]   [Full Text] [Related]  

  • 10. [Mechanism and management of airway hypersecretion in obstructive lung disease].
    Tamaoki J
    Nihon Rinsho; 1999 Sep; 57(9):2056-61. PubMed ID: 10497406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Macrolide].
    Azuma A; Kudoh S
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():804-12. PubMed ID: 12722320
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clarithromycin: specific features of antimicrobial spectrum and clinical use].
    Budanov SV; Vasil'ev AN
    Antibiot Khimioter; 2004; 49(2):19-25. PubMed ID: 15285409
    [No Abstract]   [Full Text] [Related]  

  • 13. Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen.
    Periti P; Mazzei T
    J Chemother; 1999 Feb; 11(1):11-27. PubMed ID: 10078776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of macrolide antibiotics on secretion of MUC5AC in murine model of diffuse panbronchiolitis and related diseases].
    Yanagihara K; Kaneko Y; Kuroki M; Miyazaki Y; Hirakata Y; Mukai H; Asano K; Kadota J; Tashiro T; Kawano S
    Jpn J Antibiot; 2003 Apr; 56 Suppl A():60-5. PubMed ID: 14679750
    [No Abstract]   [Full Text] [Related]  

  • 15. [Potential role of macrolides in the treatment of COPD: current evidence. (discussion)].
    Fukuchi Y; Kudo S; Ichinose M; Yamatani M; Seemungal TA
    Jpn J Antibiot; 2009 Oct; 62(5):395-405. PubMed ID: 20055117
    [No Abstract]   [Full Text] [Related]  

  • 16. [Analysis of airway secretion caused by Chlamydophila pneumoniae and the suppressive effects brought about macrolide antibacterial agents].
    Morinaga Y; Yanagihara K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Miyashita N; Mukae H; Yamada Y; Kouno S; Kamihira S
    Jpn J Antibiot; 2009 Mar; 62 Suppl A():52-6. PubMed ID: 22452056
    [No Abstract]   [Full Text] [Related]  

  • 17. [The correlation between bronchial hypersecretion and auscultatory phenomena in patients with chronic obstructive lung disease].
    Kes P; Mimica M; Reiner Z
    Plucne Bolesti Tuberk; 1982; 34(3-4):146-56. PubMed ID: 7185065
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro activity of clarithromycin against penicillin-susceptible and penicillin-resistant strains of Streptococcus pneumoniae in a pharmacodynamic simulation model.
    Fuentes F; Sevillano D; Balcabao IP; Gómez-Lus ML; Prieto J
    J Chemother; 2000 Dec; 12(6):495-8. PubMed ID: 11154032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of azithromycin on mucus secretion from nasal epithelium].
    Shimizu T; Shimizu S; Hattori R; Mashima Y
    Jpn J Antibiot; 2003 Apr; 56 Suppl A():25-8. PubMed ID: 14679741
    [No Abstract]   [Full Text] [Related]  

  • 20. Aerosol-based efficient delivery of clarithromycin, a macrolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections.
    Togami K; Chono S; Morimoto K
    J Aerosol Med Pulm Drug Deliv; 2012 Apr; 25(2):110-5. PubMed ID: 22360316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.